trustme.bro/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim
Hidradenitis suppurativa causes patients to be overweight due to the disease process itself
the verdict
INSUFFICIENT LEANING
refutedsupported
the weight of evidence
3 sources for · 0 against

The evidence documents that hidradenitis suppurativa is frequently associated with obesity and that patients often experience weight gain over time, but it does not establish that the disease process itself causes patients to be overweight.

Evidence for · 3
2020 · cited by 2
Background: Hidradenitis suppurativa (HS) is often seen in overweight and obese patients. However, little is documented about weight gain over time in HS patients. Methods: From August 2009 to March 2018, all patients in the UCLA HS clinic were asked at initial examination about their weight gain since high school. Results: A cohort of 143 HS patients were found to have a significant mean BMI increase of 4.7 (25.5 to 30.2, p<0.0001) from high school until time of presentation (approximately a 15-year interval). Of the patients with ≥10 point BMI increase, 85.2% were women. 59.6% of women were normal weight in high school with an average BMI of 24.8 (SD 6.41, range 14-50) and 78.7% were overweight or obese at time of HS clinic intake. Hispanic HS patients were found to have more weight gain than other ethnic groups, (p=0.09) which may be clinically significant. Conclusions: Although many HS patients were normal weight or mildly overweight in high school, most become obese in early adulthood. Since obesity is thought to increase HS severity, weight management should be stressed in HS patients early on before weight gain occurs. Weight Gain Over Time in Hidradenitis Suppurativa Patients: Trends and Implications | SKIN The Journal of Cutaneous Medicine GTM banner-header ad end --> Main Article Content Shanice Alyssa McKenzie University of California, Los Angeles Nirali Patel University of California, Los Angeles Christina L Harview University of Iowa Allison K Truong Cedars-Sinai Medical Center Lucia Y Chen University of California, Los Angeles Tristan R Grogan University of California, Los Angeles Vivian Y Shi The University of Arizona Richard G Bennett University of California, Los Angeles Keck School of Medicine, University of Southern California Jennifer Lin Hsiao University of California, Los Angeles http://orcid.org/0000-0002-8843-3630 Keywords Hidradenitis Suppurativa, Metabolic Syndrome, Modifiable Risk Factors Abstract Background: Hidradenitis suppurativa (HS) is often seen in overweight and obese patients. However, little is documented about weight gain over time in HS patients. Methods: From August 2009 to March 2018, all patients in the UCLA HS clinic were asked at initial examination about their weight gain since high school. Results: A cohort of 143 HS patients were found to have a significant mean BMI increase of 4.7 (25.5 Hispanic HS patients were found to have more weight gain than other ethnic groups, (p=0.09) which may be clinically significant. Conclusions: Although many HS patients were normal weight or mildly overweight in high school, most become obese in early adulthood. Since obesity is thought to increase HS severity, weight management should be stressed in HS patients early on before weight gain occurs. References References 1. Boer J, Nazary M, Riis PT. The Role of Mechanical Stress in Hidradenitis Suppurativa. Dermatol Clin. 2016;34(1):37-43. doi:10.1016/j.det.2015.08.011 2. Shlyankevich J, Chen AJ, Kim GE, Kimball AB. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: A chart-verified case-control analysis. J Am Acad Dermatol. 2014;71(6):1144-1150. doi:10.1016/j.jaad.2014.09.012 3. Tzellos T, Zouboulis CC, Gulliver W, Cohen AD, Wolkenstein P, Jemec GBE. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: A systematic review and meta-analysis of observational studies. Br J Dermatol. 2015;173(5):1142-1155. doi:10.1111/bjd.14024 4. Egeberg A, Gislason GH, Hansen PR. Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis SuppurativaCardiovascular Events and All-Cause Mortality in Hidradenitis SuppurativaCardiovascular Events and All-Cause Mortality in Hidradenitis Suppurativa. JAMA Dermatology. 2016;152(4):429-434. doi:10.1001/jamadermatol.2015.6264 5. Nazary M, Van Der Zee HH, Prens EP, Folkerts G, Boer J. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. Eur J Pharmacol. 2011;672(1-3):1-8. doi:10.1016/j.ejphar.2011.08.047 6. Schrader AMR, Deckers IE, Van Der Zee HH, Boer J, Prens EP. Hidradenitis suppurativa: A retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol. 2014;71(3):460-467. doi:10.1016/j.jaad.2014.04.001 7. Riis PT, Saunte DM, Benhadou F, Marmol V, Guillem P, Beksac B. Low and high body mass index in hidradenitis suppurativa patients — different subtypes ? J Eur Acad Dermatology Venereol. 2018;32(2):307-312. doi:10.1111/jdv.14599 8. Thomas CL, Gordon KD, Mortimer PS. Rapid resolution of hidradenitis suppurativa after bariatric surgical intervention. Clin Exp Dermatol. 2014;39(3):315-318. doi:10.1111/ced.12269 9. Gallagher C, Kirthi S, Burke T, O’Shea D, Tobin AM. Remission of hidradenitis suppurativa after bariatric surgery. JAAD Case Reports. 2017;3(5):436-437. doi:10.1016/j.jdcr.2017.06.008 10. Gierach M, Gierach J, Ewertowska M, Arndt A, Junik R. Correlation between Body Mass Index and Waist Circumference in Patients with Metabolic Syndrome. ISRN Endocrinol. 2014;2014(514589). 11. Shalom G, Freud T, Harman-Boehm I, Polishchuk I, Cohen AD. Hidradenitis suppurativa and metabolic syndrome: A comparative cross-sectional study of 3207 patients. Br J Dermatol. 2015;173(2):464-470. doi:10.1111/bjd.13777 12. Fryar CD, Gu Q, Ogden CL, Flegal KM. Anthropometric Reference Data for Children and Adults: United States, 2011-2014. Vital Health Stat 3. 2016;(39):1-46. Article Sidebar PDF Published 2020-03-08 DOI: https://doi.org/10.25251/skin.4.2.15 Article Details How to Cite 1. Weight Gain Over Time in Hidradenitis Suppurativa Patients: Trends and Implications. J of Skin . 2020;4(2):171-176. doi: 10.25251/skin.4.2.15 More Citation Formats ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA Issue Vol. 4 No. 2 (2020) Section Brief Articles This work is licensed under a Creative Commons Attribution 4.0 International License . All authors retain copyright in their articles.
See more details
The analysis

rails:sufficiency:partial_only:for=0+3p:against=0+0p | v55:multi_partial_one_side:lean=lean_partial:for:one_sided

More for · 2
2026 · cited by 0
<b>Background:</b> Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease, which presents with painful nodules, abscesses and sinus tracts. Patients suffer from pain, drainage and worsening of mental health and quality of life. Treatment is often difficult. HS is typically associated with obesity and metabolic syndrome; thus, antidiabetics, especially GLP-1 agonists, present a potential therapy option. The aim of this review was to analyze the effects of GLP-1 agonists on patients with HS, including on their cardiovascular risk and quality of life. <b>Methods:</b> A literature search was conducted on Embase and PubMed, yielding 300 papers, of which 10 were used for this review. <b>Results:</b> HS patients using GLP-1 agonists showed improved clinical course with less pain and suppuration. Further, patients' quality of life and mental health improved and their cardiovascular risk was reduced. Inflammatory parameters showed no significant changes. Patients receiving a higher drug dose of GLP-1 agonists were more likely to show clinical improvement. A reduction in weight or BMI did not correlate with improvements in Hurley stage, pain or depression. Hence, HS patients could be treated with GLP-1 agonists. <b>Conclusions:</b> Therefore, whether patients' improvement is due to weight loss, or other mechanisms, i.e., GLP-1 agonists' anti-inflammatory properties, remains to be determined in further studies. 2745 jclinmed Journal of Clinical Medicine J Clin Med Multidisciplinary Digital Publishing Institute (MDPI) PMC13116881 13116881 13116881 42074711 10.3390/jcm15082909 Effects of GLP-1 Agonists on Patients with Hidradenitis Suppurativa: A Systematic Review Caliezi Annik 1 * Hosseini Aref 1 2 Wolf Ronald 1 Seyed Jafari Seyed Morteza 1 Krajewski Piotr K Academic Editor 1 Department of Dermatology, Inselspital, Anna-Seiler-Allee 33, 3010 Bern, Switzerland 2 Institute of Pharmacology, University of Bern, Rosenbühlgasse 27, 3010 Bern, Switzerland * Correspondence: annik.caliezi@gmx.net 11 4 2026 15 8 2909 2909 28 4 2026 © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license . Abstract Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease, which presents with painful nodules, abscesses and sinus tracts. Patients suffer from pain, drainage and worsening of mental health and quality of life. Treatment is often difficult. HS is typically associated with obesity and metabolic syndrome; thus, antidiabetics, especially GLP-1 agonists, present a potential therapy option. A reduction in weight or BMI did not correlate with improvements in Hurley stage, pain or depression. Hence, HS patients could be treated with GLP-1 agonists. Conclusions: Therefore, whether patients’ improvement is due to weight loss, or other mechanisms, i.e., GLP-1 agonists’ anti-inflammatory properties, remains to be determined in further studies. Keywords: effects, glucagon like peptide 1 receptor agonists, hidradenitis suppurativa, quality of life, cardiovascular risk status released display-pdf yes is-olf no is-manuscript no is-preprint no is-journal-matter no is-scanned no is-retracted no Received 2026 Feb 17; Revised 2026 Mar 24; Accepted 2026 Mar 30; Collection date 2026 Apr. 1. Introduction Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease where patients suffer from painful nodules, abscesses and sinus tracts typically located in intertriginous areas [ 1 ]. Patients experience pain, malodorous drainage and a great negative impact on their mental health [ 2 , 3 , 4 ]. All these factors together cause HS patients to have one of the worst quality of life impairments among dermatologic patients [ 5 ]. Materials and Methods We conducted a literature search on Embase (23 October 2025) and PubMed (26 October 2025) using the following key words and variations or abbreviations of them: “Hidradenitis suppurativa”, “acne inversa”, “Verneuil’s disease”, “pyoderma fistulans significa”, “apocrine acne”, “Incretin mimetic”, “glucagon like peptide 1 agonist”, “glucagon like peptide 1 analogue”. In addition, the drug names of 15 GLP-1 agonists that are currently approved or being evaluated in clinical trials, such as “semaglutide” or “efpeglenatide”, and brand names of 18 medications currently on the market, e.g., “Mounjaro” or “Xultophy”, were used to extend the search. Abbreviations The following abbreviations are used in this manuscript (in order of appearance): HS Hidradenitis suppurativa T2DM Type 2 diabetes mellitus NAFLD Non-alcoholic fatty liver disease GLP-1 agonists Glucose-like-peptide-1 agonists HS-PGA HS-Physician Global Assessment RR Risk ratio CI Confidence interval ER Emergency Room BMI Body Mass Index (A)MI (Acute) Myocardial Infarction aOR Adjusted odds ratio QoL Quality of Life DLQI Dermatology Life Quality Index BDI Beck’s Depression Index VAS Visual Analogue Scale SD Standard deviation AI Artificial intelligence Supplementary Materials The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm15082909/s1 , Table S1: Risk of Bias assessment.; PRISMA 2020 Checklist; PRISMA-S Checklist. Complete Search String Embase (exp Hidradenitis Suppurativa/ OR (hidradenitis suppurativ* OR suppurative hidradenitis OR HS OR acne inversa OR verneuil* disease OR inverse acne OR pyodermia fistulans significa OR apocrine acne).ti,ab,kw.) AND ((Incretin mimetic* OR glucagon like peptide receptor agonist OR glucagon like peptide 1 receptor agonist OR GLP receptor agonist OR GLP1 receptor agonist OR GLP 1 receptor agonist OR Glucagon like peptide RA OR Glucagon like peptide 1 RA OR GLP RA OR GLP1 RA OR GLP 1 RA OR GLP1R agonist OR glucagonlike peptide OR glucagonlike peptide 1 OR glucagonlike peptide receptor OR glucagonlike peptide receptor agonist OR glucagonlike peptide RA OR glucagonlike peptide 1
cited by 0
What is hidradenitis suppurativa (HS)? Hidradenitis suppurativa (HS) is a chronic skin disease. Another name for it is acne inversa. It causes painful, boil-like lumps that form under the skin. It often affects areas where the skin rubs together, such as your armpits and groin. The lumps become inflamed and painful. They often break open, causing abscesses that drain fluid and pus. As the abscesses heal, they can cause scarring of the skin. What causes hidradenitis suppurativa (HS)? The lumps in HS form because of blockages of the hair follicles. The blocked hair follicles trap bacteria, which leads to inflammation and rupture. In most cases, the cause of the blockages is unknown. Genetics, environment, and hormonal factors may play a role. Some cases of HS are caused by changes in certain genes. HS is not caused by bad hygiene, and it cannot be spread to others. Who is more likely to get hidradenitis suppurativa (HS)? HS usually starts after puberty, usually in the teens or twenties. It is more common in: Women People who are Black People with a family history of HS People who are overweight or have obesity People who smoke What are the symptoms of hidradenitis suppurativa (HS)? You Are Here: Home &rarr; Health Topics &rarr; Hidradenitis Suppurativa URL of this page: https://medlineplus.gov/hidradenitissuppurativa.html Hidradenitis Suppurativa Also called: Acne inversa, Suppurative hidradenitis On this page Basics Summary Start Here Learn More Genetics See, Play and Learn Images Research Clinical Trials Journal Articles Resources Find an Expert For You Teenagers Summary What is hidradenitis suppurativa (HS)? Hidradenitis suppurativa (HS) is a chronic skin disease. Another name for it is acne inversa. It causes painful, boil-like lumps that form under the skin. It often affects areas where the skin rubs together, such as your armpits and groin. The lumps become inflamed and painful. They often break open, causing abscesses that drain fluid and pus. As the abscesses heal, they can cause scarring of the skin. What causes hidradenitis suppurativa (HS)? The lumps in HS form because of blockages of the hair follicles. The blocked hair follicles trap bacteria, which leads to inflammation and rupture. In most cases, the cause of the blockages is unknown. Genetics, environment, and hormonal factors may play a role. Some cases of HS are caused by changes in certain genes . HS is not caused by bad hygiene, and it cannot be spread to others. Who is more likely to get hidradenitis suppurativa (HS)? HS usually starts after puberty, usually in the teens or twenties. It is more common in: Women People who are Black People with a family history of HS People who are overweight or have obesity People who smoke What are the symptoms of hidradenitis suppurativa (HS)? The symptoms of HS include: Small pitted areas of skin containing blackheads Painful, red, lumps that get bigger and break open. This causes abscesses that drain fluid and pus. They may itch and have an unpleasant odor. The abscesses heal very slowly, recur over time, and can lead to scarring and tunnels under the skin. HS can be mild, moderate, or severe: In mild HS, there are only one or a few lumps in one area of the skin. A mild case will often get worse, becoming a moderate disease. Moderate HS includes recurrences of the lumps that get bigger and break open. The lumps form in more than one area of the body. With severe HS, there are widespread lumps, scarring, and chronic pain that may make it hard to move. Because of the difficulty of dealing with the disease, people with HS are at risk for depression and anxiety . How is hidradenitis suppurativa (HS) diagnosed? There is no specific test for HS. It can be hard to diagnose in the early stages because it can look like pimples or acne . To make a diagnosis, your health care provider: Will ask about your medical history and your symptoms Will look at the lumps on your skin May take a sample of the skin or pus (if there is any) and send it to a lab to be tested Your provider may refer you to a dermatologist (skin doctor) to get a diagnosis or treatment. What are the treatments for hidradenitis suppurativa? There is no cure for HS. Treatments focus on the symptoms, but they are not always effective for everyone. The treatments depend on how severe the disease is and may include: Medicines , including steroids , antibiotics , pain relievers , and medicines that flight inflammation. It may also help if you can avoid things that can irritate your skin, by: Wearing loose-fitting clothing Staying at a healthy weight Quitting smoking Avoiding heat and humidity Being careful not to injure your skin Start Here Hidradenitis Suppurativa (HS) (National Institute of Arthritis and Musculoskeletal and Skin Diseases) Also in Spanish Hidradenitis Suppurativa: Overview (American Academy of Dermatology) Genetics Hidradenitis suppurativa: MedlinePlus Genetics (National Library of Medicine) Images Hidradenitis Suppurativa (VisualDX) Clinical Trials ClinicalTrials.gov: Hidradenitis Suppurativa (National Institutes of Health) Journal Articles References and abstracts from MEDLINE/PubMed (National Library of Medicine) Article: Reorganization and functional divergence of the CD4+ memory T cell compartment... Hidradenitis Suppurativa -- see more articles Find an Expert Find a Dermatologist (American Academy of Dermatology) National Institute of Arthritis and Musculoskeletal and Skin Diseases Also in Spanish Teenagers Hidradenitis Suppurativa (VisualDX) Topic Image Related Health Topics Sweat National Institutes of Health The primary NIH organization for research on Hidradenitis Suppurativa is the National Institute of Arthritis and Musculoskeletal and Skin Diseases Disclaimers MedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites.
Everything we examined (3)
This check searched the claim as stated. It did not run a separate search for evidence against it.
  1. Effects of GLP-1 Agonists on Patients with Hidradenitis Suppurativa: A Systematic Review.peer-reviewedno side taken
  2. Weight Gain Over Time in Hidradenitis Suppurativa Patients: Trends and Implicationspeer-reviewedno side taken
  3. MedlinePlus: Hidradenitis Suppurativaofficial-recordno side taken
The paper trail · every fact has a biography
held for human review08 Aug 2026
This receipt carries no identity, shared or not. Sharing publishes your connection to it, not your data.
Check your own claim
Challenge the receipt
trust me, bro: win the argument, pass the class, survive peer review.
This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt